CSL Behring: Difference between revisions

Latest revision as of 10:59, 15 February 2025

CSL Behring[edit]

CSL Behring is a global biotechnology company that specializes in the development and delivery of innovative therapies for people with rare and serious diseases. The company is a leader in the field of plasma protein biotherapeutics and is dedicated to improving the quality of life for patients worldwide.

History[edit]

CSL Behring was formed as a result of the merger between CSL Limited and Aventis Behring in 2004. CSL Limited, an Australian company, acquired Aventis Behring, a division of the French pharmaceutical company Aventis, to expand its global presence in the biopharmaceutical industry. The merger combined CSL's expertise in plasma fractionation with Aventis Behring's extensive product portfolio.

Products and Services[edit]

CSL Behring offers a wide range of products and services, primarily focused on the treatment of rare and serious conditions. These include:

Immunoglobulins: Used to treat immune deficiencies and autoimmune diseases.
Coagulation factor concentrates: For the treatment of bleeding disorders such as hemophilia.
Albumin: Used in critical care settings to treat shock and burns.
Alpha-1 proteinase inhibitor: For the treatment of Alpha-1 antitrypsin deficiency.

Research and Development[edit]

CSL Behring invests heavily in research and development to advance the science of biotherapeutics. The company focuses on discovering new therapies and improving existing ones to address unmet medical needs. CSL Behring's R&D efforts are supported by a global network of research facilities and collaborations with leading academic institutions.

Global Presence[edit]

CSL Behring operates in over 30 countries and has manufacturing facilities in the United States, Germany, Switzerland, and Australia. The company's global reach allows it to deliver life-saving therapies to patients around the world.

Corporate Social Responsibility[edit]

CSL Behring is committed to corporate social responsibility and actively engages in initiatives that support patient communities, promote health and wellness, and protect the environment. The company collaborates with patient advocacy groups and healthcare professionals to improve access to therapies and enhance patient care.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-'''CSL Behring''' is a global [[biotechnology]] company that develops and delivers innovative [[biotherapies]] and [[influenza vaccines]] to protect public health and help people with life-threatening medical conditions live full lives. As a subsidiary of the [[CSL Limited]] group, CSL Behring's focus is on the development of products to treat [[coagulation disorders]], [[primary immune deficiencies]], [[hereditary angioedema]], [[neurological disorders]], and [[inherited respiratory disease]], among other serious medical conditions.
+== CSL Behring ==
-==History==
+[[File:CSL_Behring_logo.png|thumb|right|CSL Behring logo]]
-CSL Behring traces its roots back to the establishment of the Commonwealth Serum Laboratories (CSL) in [[Australia]] in 1916, as a response to the country's need for self-sufficiency in the production of vital [[medicines]]. Over the years, CSL has grown from a national entity into a global [[biopharmaceutical]] company. In 2007, CSL Limited rebranded its plasma products division as CSL Behring, reflecting its commitment to providing life-saving [[therapies]] derived from human plasma.
-==Products and Services==
+'''CSL Behring''' is a global biotechnology company that specializes in the development and delivery of innovative therapies for people with rare and serious diseases. The company is a leader in the field of [[plasma protein biotherapeutics]] and is dedicated to improving the quality of life for patients worldwide.
-CSL Behring offers a wide range of products that include [[plasma-derived therapies]] and [[recombinant]] products. These therapies are used in the treatment of various conditions such as:
-* [[Hemophilia]]: CSL Behring produces coagulation factor products for the treatment of hemophilia A and B.
+== History ==
-* [[Immune Deficiencies]]: The company provides immunoglobulin therapies for individuals with primary and secondary immune deficiencies.
-* [[Hereditary Angioedema]]: CSL Behring offers treatments for managing and preventing hereditary angioedema attacks.
-* [[Specialty Products]]: This includes products for the treatment of neurological disorders and inherited respiratory diseases.
-CSL Behring is also involved in the research and development of new therapies, with a strong pipeline of products aimed at addressing unmet medical needs.
+CSL Behring was formed as a result of the merger between CSL Limited and Aventis Behring in 2004. CSL Limited, an Australian company, acquired Aventis Behring, a division of the French pharmaceutical company Aventis, to expand its global presence in the biopharmaceutical industry. The merger combined CSL's expertise in plasma fractionation with Aventis Behring's extensive product portfolio.
-==Research and Development==
+== Products and Services ==
-Research and development (R&D) are central to CSL Behring's mission. The company invests heavily in R&D to improve existing therapies and to discover new treatments. CSL Behring's R&D efforts are focused on the areas of immunology, hematology, cardiovascular and metabolic diseases, respiratory diseases, and transplant therapy.
-==Global Presence==
+CSL Behring offers a wide range of products and services, primarily focused on the treatment of rare and serious conditions. These include:
-With its headquarters in [[King of Prussia, Pennsylvania]], USA, CSL Behring operates in more than 30 countries around the world. The company's global reach allows it to serve patients and healthcare professionals with cutting-edge therapies and ensures that its products are accessible to those in need.
-==Corporate Responsibility==
+* [[Immunoglobulins]]: Used to treat immune deficiencies and autoimmune diseases.
-CSL Behring is committed to corporate responsibility, with a focus on patient access to therapies, environmental sustainability, and ethical business practices. The company supports patient organizations and initiatives that aim to improve the quality of life for people with rare and serious diseases.
+* [[Coagulation factor concentrates]]: For the treatment of bleeding disorders such as [[hemophilia]].
+* [[Albumin]]: Used in critical care settings to treat shock and burns.
+* [[Alpha-1 proteinase inhibitor]]: For the treatment of [[Alpha-1 antitrypsin deficiency]].
-==Conclusion==
+== Research and Development ==
-CSL Behring plays a crucial role in the biotechnology industry, providing essential therapies for patients with rare and serious conditions. Through its commitment to innovation, global presence, and corporate responsibility, CSL Behring continues to make a significant impact on public health and individual lives around the world.
+CSL Behring invests heavily in [[research and development]] to advance the science of biotherapeutics. The company focuses on discovering new therapies and improving existing ones to address unmet medical needs. CSL Behring's R&D efforts are supported by a global network of research facilities and collaborations with leading academic institutions.
+== Global Presence ==
+CSL Behring operates in over 30 countries and has manufacturing facilities in the United States, Germany, Switzerland, and Australia. The company's global reach allows it to deliver life-saving therapies to patients around the world.
+== Corporate Social Responsibility ==
+CSL Behring is committed to [[corporate social responsibility]] and actively engages in initiatives that support patient communities, promote health and wellness, and protect the environment. The company collaborates with patient advocacy groups and healthcare professionals to improve access to therapies and enhance patient care.
+== Related Pages ==
+* [[Biotechnology]]
+* [[Plasma (blood)]]
+* [[Pharmaceutical industry]]
+* [[Rare disease]]
 [[Category:Biotechnology companies]]
 [[Category:Pharmaceutical companies]]
-{{pharma-stub}}
+[[Category:CSL Limited]]
-{{No image}}